Aims & Scope
Current Pharmacogenomics and Personalized Medicine (CPPM) is a transdisciplinary, peer-reviewed biomedical
journal that reports new findings and cutting-edge concepts in all areas of
pharmacology. Special consideration is given to articles on pharmacogenomics
and personalized medicine. CPPM is an accelerator for global personalized
medicine and pharmacogenomics, as well as preclinical and clinical
pharmacology. Importantly, the journal provides a multi-disciplinary,
integrated platform from cell to society to address diagnostics and the responsible
pharmacogenomics applications in developing countries and the entire range of
translational science from bench
to bedside in various therapeutic areas, such as oncology, neuropharmacology, and cardiovascular and endocrine diseases,
amongst others.
CPPM
cooperates with the Ibero-American Network of Pharmacogenetics and the Pacific
Rim Association for Clinical Pharmacogenetics and welcomes peer-reviewed contributions
from authors in any global region.
The journal's scope is defined by four interconnected aims. First,
we are interested in genomics/postgenomics biotechnologies and diagnostics that
enable global personalized medicine science (including and beyond
pharmacogenomics)
as long as they explain person-to-person and population differences in disease
susceptibility or response to a health intervention and can be substantiated. Second, we approach
personalized medicine as ‘personalized health interventions’ focusing primarily
on drug therapy, but also other interventions, such as nutrition, vaccines, surgical devices, and emerging cell-based
therapies that collectively contribute to healthcare. Third, we strive to
integrate molecular and clinical investigation with public policy, global
health diplomacy,
and social studies of biotechnology, which collectively shape postgenomics future(s) and innovation
trajectories in life sciences. Fourth, we are interested in all aspects of
translational pharmacology,
from preclinical to clinical applications in any therapeutic area that will
advance the practice of medicine for the benefit of patients worldwide, including
non-communicable diseases as well as infectious diseases in the post-COVID
world.
Priority will be given to expert reviews/ mini-reviews
and research articles that include original ideas and findings related to the
scope and mandate of the journal. Unsolicited submissions are welcome.
